South Africa Recombinant Protein Therapeutics Cdmo Market Size & Outlook

The recombinant protein therapeutics cdmo market in South Africa is expected to reach a projected revenue of US$ 363.7 million by 2030. A compound annual growth rate of 12.6% is expected of South Africa recombinant protein therapeutics cdmo market from 2024 to 2030.

Revenue, 2023 (US$M)
$158.9
Forecast, 2030 (US$M)
$363.7
CAGR, 2024 - 2030
12.6%
Report Coverage
South Africa

South Africa recombinant protein therapeutics cdmo market, 2018-2030 (US$M)

South

Related Markets

South Africa recombinant protein therapeutics cdmo market highlights

  • The South Africa recombinant protein therapeutics cdmo market generated a revenue of USD 158.9 million in 2023 and is expected to reach USD 363.7 million by 2030.
  • The South Africa market is expected to grow at a CAGR of 12.6% from 2024 to 2030.
  • In terms of segment, interferons was the largest revenue generating type in 2023.
  • Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.


Recombinant protein therapeutics cdmo market data book summary

Market revenue in 2023USD 158.9 million
Market revenue in 2030USD 363.7 million
Growth rate12.6% (CAGR from 2023 to 2030)
Largest segmentInterferons
Fastest growing segmentGrowth Hormones
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationGrowth Hormones, Interferons, Vaccines, Immunostimulating Agents
Key market players worldwideLonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences


Other key industry trends

  • In terms of revenue, South Africa accounted for 0.8% of the global recombinant protein therapeutics cdmo market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Middle East & Africa, Saudi Arabia recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
  • UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 312.8 million by 2030.

Interferons was the largest segment with a revenue share of 21.52% in 2023. Horizon Databook has segmented the South Africa recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.


The existing need for advanced therapeutics & their manufacturing is a major factor driving the demand for recombinant protein therapeutics services in South Africa. This shows the existing growth possibilities for clinical research in the country. In addition, the entry & focus of small-scale CDMOs in South Africa are unveiling the future possibilities for advanced therapeutics development and manufacturing in the country.


The growing R&D activities and well-established research activities, which comply with the ICH and FDA standards; a diverse population; and low cost of trials are some of the primary factors expected to drive the market growth.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Recombinant Protein Therapeutics CDMO Market Companies

Name Profile # Employees HQ Website

South Africa recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)

South Africa Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)

South Africa recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more